WASHINGTON, D.C. — The following statement was issued by David Mitchell, a cancer patient and founder of Patients For Affordable Drugs Now, in response to the Senate Judiciary Committee’s bipartisan, unanimous passage of a package of four bills that would lower drug prices and promote innovation by curbing anticompetitive behavior by pharmaceutical corporations:
“We applaud Chairman Durbin, Ranking Member Grassley, and members of the Senate Judiciary Committee for passing legislation to crack down on anticompetitive drug industry practices and strengthen incentives for true biomedical innovation. This package of bills takes important steps to address abuses of our patent system that inhibit innovation, block competition, and allow drug corporations to raise prices without restraint.
“Today’s unanimous vote also lends important momentum to the larger work in Congress to fix our broken drug pricing system. We will continue to work with Congress this year to enact other needed reforms, including allowing Medicare to negotiate lower drug prices for all Americans.”
WASHINGTON, D.C. — Patients For Affordable Drugs founder David Mitchell will tell his story of living with incurable blood cancer and will debunk Big Pharma’s claim that patients won’t get innovative drugs without paying high prices at a 10:00 AM hearing today on rising drug prices.
Read his full testimony here.
Mitchell’s testimony will highlight stories of patients skipping doses and going into debt to afford rising prescription drug prices. And he’ll focus on the fact that right now, nearly 1 in 3 adults report not taking their medicines as prescribed because of the cost. He’ll also discuss three legislative solutions to fix our broken system:
Key Points From Mitchell’s Testimony:
Patients For Affordable Drugs is a national patient organization focused exclusively on policies to lower prescription drug prices. We amplify the voices of Americans struggling under crushing drug prices to make policymakers and elected officials see the heavy toll of high-priced drugs. Patients For Affordable Drugs does not accept contributions from any organizations that profit from the development or distribution of prescription drugs.
WASHINGTON, D.C. — On Tuesday, May 7 at 10:00 AM, Patients For Affordable Drugs Founder David Mitchell will testify before the Senate Judiciary Committee during a hearing on rising prescription drug prices.
Mitchell will discuss his journey as a patient with incurable blood cancer and will offer a number of solutions to lower drug prices. He will encourage bipartisan action to address this issue, including reforming the country’s patent laws, ending the days of monopoly pricing power without taxpayer negotiations, and forcing transparency from drug middlemen.
WHAT: Full Senate Judiciary Committee Hearing, “Intellectual Property and the Price of Prescription Drugs: Balancing Innovation and Competition”
WHEN: Tuesday, May 7 at 10:00 AM
WHERE: Dirksen Senate Office Building 226, or watch online
Joshua D. Barker, Director of the South Carolina Department of Health and Human Services
David Mitchell, President and Founder of Patients For Affordable Drugs
James Stansel, Executive Vice President and General Counsel of the Pharmaceutical Research and Manufacturers of America
Michael Carrier, Professor of law at Rutgers Law School
David S. Olson, Associate Professor at Boston College Law School
WASHINGTON, D.C. — Patients For Affordable Drugs Now applauded and thanked the Senate Judiciary Committee for passing the bipartisan CREATES Act — a bill that aims to lower drug prices by speeding generics to market. In response to the committee voting 16 to 5 to move the bill for consideration by the full Senate, Executive Director Ben Wakana issued the following statement:
“Months of intense opposition from Big Pharma could not kill this bill, and nothing will stop patients from demanding solutions like the CREATES Act to lower drug prices. Chairman Grassley, Senator Leahy, and all committee members voting yes deserve credit for fighting for patients today. Drug corporations should stop safeguarding bad actors and instead focus on getting affordable medicine to Americans who need it.”